Floatz logo

ANTI-TRAIL-R2 MOAB

Liver Neoplasms

Daiichi Sankyomonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

24 Active assets in the Liver Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Tehran University of Medical Sciences
Phase 4BBB
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
CHLORHEXIDINE
Changhua Christian Hospital
Phase 4BB
Talaporfin
Light Sciences Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

ANTI-TRAIL-R2 MOAB is also rated in:

breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
57 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →